These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Economic evaluation of sevelamer in patients with end-stage renal disease. Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182 [TBL] [Abstract][Full Text] [Related]
23. Sevelamer worsens metabolic acidosis in hemodialysis patients. De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432 [TBL] [Abstract][Full Text] [Related]
24. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients. Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864 [TBL] [Abstract][Full Text] [Related]
25. Control of hyperphosphatemia among patients with ESRD. Coladonato JA J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245 [TBL] [Abstract][Full Text] [Related]
27. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Fan S; Ross C; Mitra S; Kalra P; Heaton J; Hunter J; Plone M; Pritchard N Nephrol Dial Transplant; 2009 Dec; 24(12):3794-9. PubMed ID: 19666658 [TBL] [Abstract][Full Text] [Related]
28. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Suki WN; J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452 [TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. Tzanno-Martins C; Biavo BM; Ferreira-Filho O; Ribeiro-Junior E; João-Luiz MV; Degaspari S; Scavone C; Kawamoto E Int J Immunopathol Pharmacol; 2014; 27(1):25-35. PubMed ID: 24674676 [TBL] [Abstract][Full Text] [Related]
30. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease]. Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197 [TBL] [Abstract][Full Text] [Related]
31. Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. Heinrich T; Heidt H; Hafner V; Schmidt-Gayk H; Jenetzky E; Walter-Sack I; Mikus G; Bommer J Nephrol Dial Transplant; 2008 Sep; 23(9):2861-7. PubMed ID: 18388122 [TBL] [Abstract][Full Text] [Related]
32. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. Autissier V; Damment SJ; Henderson RA J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733 [TBL] [Abstract][Full Text] [Related]